RELMADA THERAPEUTICS, INC. Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired
RELMADA THERAPEUTICS, INC. (RLMD) reported Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired of $3.75 million for the 9-month period ending 2014-03-31, per its 10-Q filed 2015-05-15.
Discontinued › Notes › Goodwill and Other
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired · last filed 2015-05-15
- RELMADA THERAPEUTICS, INC. research and development asset acquired other than through business combination, fair value acquired for the quarter ending 2014-03-31 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 3 month | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 6 month | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 9 month |
|---|---|---|---|
| 2014-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-15 | $3.75M 10-Q · filed 2015-05-15 | |
| 2013-12-31 | $3.75M 10-Q · filed 2015-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |